Analysts Offer Insights on Healthcare Companies: Natera (NTRA), EDAP TMS (EDAP) and Apyx Medical (APYX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Natera (NTRA – Research Report), EDAP TMS (EDAP – Research Report) and Apyx Medical (APYX – Research Report) with bullish sentiments.

Natera (NTRA)

Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Natera today. The company’s shares closed last Thursday at $46.23.

According to TipRanks.com, Nowak is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.6% and a 30.3% success rate. Nowak covers the Healthcare sector, focusing on stocks such as NeuroOne Medical Technologies, InfuSystem Holdings, Inc., and Accelerate Diagnostics.

Natera has an analyst consensus of Strong Buy, with a price target consensus of $64.20, implying a 35.2% upside from current levels. In a report issued on November 2, Leerink Partners also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

EDAP TMS (EDAP)

In a report released today, Eric Martinuzzi from Lake Street maintained a Buy rating on EDAP TMS, with a price target of $16.00. The company’s shares closed last Thursday at $6.07, close to its 52-week low of $5.78.

According to TipRanks.com, Martinuzzi is a 2-star analyst with an average return of 0.1% and a 37.7% success rate. Martinuzzi covers the Technology sector, focusing on stocks such as Genius Sports Limited, CommVault Systems, and Extreme Networks.

EDAP TMS has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.

Apyx Medical (APYX)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Apyx Medical today. The company’s shares closed last Thursday at $1.83, close to its 52-week low of $1.31.

According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.4% and a 32.9% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Champions Oncology, and Simulations Plus.

Apyx Medical has an analyst consensus of Moderate Buy, with a price target consensus of $5.72, which is a 204.3% upside from current levels. In a report released today, Lake Street also assigned a Buy rating to the stock with a $9.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NTRA:

• NTRA Earnings this Week: How Will it Perform?
• Charles River price target lowered to $220 from $235 at Morgan Stanley
• Natera announced updated data from GALAXY arm of CIRCULATE-Japan trial
• Natera price target lowered to $70 from $80 at Piper Sandler
• DermTech, Natera can benefit from California biomarker law, says Craig-Hallum